Table 1.
Cyberknife®-SBRT: clinical characteristics of 100 patients
| T Stage | Patients |
|---|---|
| T1c |
44 (44%) |
| T2a-b |
29 (29%) |
| (T2a, 10 pts) |
|
| (T2b, 19 pts) |
|
| T2c |
27 (27%) |
|
Gleason score |
|
| <6 (2+2, 2+3, 3+2) |
8 (8%) |
| 6 (3+3) |
76 (76%) |
| >7 (3+4 11 pts, 4+3 4 pts, 5+5 1 pt) |
16 (16%) |
|
PSA |
|
|
at diagnosis |
ng/ml |
| All patients |
7.72 ng/ml |
| SBRT (71 pts) |
6.48 ng/ml |
| SBRT+ADT (29 pts) |
10.77 ng/ml |
|
Pre-treatment |
ng/ml |
| All patients |
5.03 ng/ml |
| SBRT (71 pts) |
6.31 ng/ml |
| SBRT+ADT (29 pts) |
1.90 ng/ml |
|
Risk category |
Patients |
| Low (PSA <10, GS 6, T1c, T2a) |
41 (41%) |
| Intermediate (PSA >10, GS 7 or T2b-c) |
42 (42%) |
| High (PSA >20, GS 8–10, 2 Int. risk features) |
17 (17%) |
|
Prostate volume ( medium 33 cc.) |
|
| ≤ 33 cc. |
51 (51%) |
| > 33 cc. |
49 (49%) |
|
TURP before SBRT (1–16 years) |
7 (7%) |
|
ADT |
|
| Before SBRT (median 6 months) |
8 (27%) |
| Concomitant and after SBRT (median 12 months) | 21 (73%) |
SBRT = Stereotactic Body Radiation Therapy.
ADT = Androgen Deprivation Therapy.
TURP = Transurethral resection of the prostate.